Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal danish women: No relation to bone markers or serum lipoproteins

Climacteric

Volumn 3, Issue 2, 2000, Pages 84-91

  Bagger, Y Z ^a   Hassager, C ^a   Heegaard, A M ^a,b   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b OSTEOPRO A/S   (Denmark)

Author keywords

Bone markers; Cardiovascular disease; Hormone replacement therapy; Osteoporosis; Polymorphisms of vdr and er genes; Serum lipoproteins

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 1; ESTROGEN RECEPTOR; LIPOPROTEIN; OSTEOCALCIN; RESTRICTION ENDONUCLEASE; VITAMIN D RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BONE TURNOVER; CARDIOVASCULAR DISEASE; DENMARK; DNA DETERMINATION; DNA POLYMORPHISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; NORMAL HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0033854571     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697130009167609     Document Type: Article

References (24)

1. 1. Gorodeski GI, Utian WH. Epidemiology and risk factors of cardiovascular disease in postmenopausal women. In Lobo RA, ed. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. New York: Raven Press, 1994:199-221
2. 2. Melton LJ. Hip fractures: a worldwide problem today and tomorrow. Bone 1993;14:1-8
3. 3. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Ebert S. Genetic determinants of bone mass in adults: twin study. J Clin Invest 1987;80:706-10
4. 4. Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med 1989;320:554-8
5. 5. Slemenda CW, Christian JC, Williams CJ, Norton JA, Johnston CC Jr. Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res 1991;6:561-7
6. 6. Morrison NA, Yeoman R, Kelly PJ, Eisman JA. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 1992;89: 6665-9
7. 7. Kelly PJ, Hopper JH, Macaskili GT, Pocock NA, Sambrook PN, Eisman JA. Genetic factors in bone turnover. J Clin Endocrinol Metab 1991;72:808-13
8. 8. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV. Prediction of bone density from vitamin D receptor alleles. Nature (London) 1994;347:284-7
9. 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998; 338:1016-21
10. 10. Van Leeuwen JPTM, Uitterlinden AG, Burger H, Huang Q, Birkenhager JC, Pols HAP. Estrogen receptor genotypes and bone mineral density: the Rotterdam study. In Pols HAP, Johnston CC, Delmas PD, eds. Osteoporosis. Amsterdam: Elsevier Science, 1996:171-3
11. 11. Garnero P, Borel O, Sornay-Rendu E, Arlot ME, Delmas PD. Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFFLY Study. J Bone Miner Res 1996;11:827-34
12. 12. Kobayashi S, Inoue S, Hosoi T, Quchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 1996;11:306-11
13. 13. Han KK, Moon IG, Kang YS, Chung HY, Min HK, Han IK. Nonassociation of estrogen receptor genotype with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab 1997;82:991-5
14. 14. Jørgensen HL, Scøller J, Sand JC, Bjuring M, Hassager C, Christiansen C. Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone loss: cross sectional and longitudinal population study. Br Med J 1996;13:586-90
15. 15. Bagger YZ, Jørgensen HL, Heegaard A, Bayer L, Hansen L, Hassager C. No major effect of estrogen receptor gene polymorphisms on bone mineral density or bone loss in postmenopausal Danish women. Bone 2000;26:111-16
16. 16. Losordo DW, Kearney M, Kim EA,Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and artherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10
17. 17. Van der Mooren MJ, Mijatovic V, van Baal WM, Stehouwer CD. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas 1998;30: 27-36
18. 18. Vadlamudi S, MacLean P, Israel RG, et al. Effect of oral combined hormone replacement therapy on plasma lipids and lipoproteins. Metabolism 1998;47:1222-6
19. 19. Wahl P, Waiden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862-7
20. 20. Hulley S, Grady D, Furbery C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-13
21. 21. Matsubara Y, Murata M, Kawano K, et al. Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol 1997;17:3006-12
22. 22. Christiansen C, Christensen MS, McNaur P, Hagen C, Stocklund K, Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9
23. 23. Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronaary artery disease. Lancet 1993;342:133-6
24. 24. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20: 452-7